- Home
- BCG vs RPTX Comparison
BCG vs RPTX Comparison
Compare BCG & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- RPTX
- Stock Information
- Founded
- BCG 2016
- RPTX 2016
- Country
- BCG United States
- RPTX Canada
- Employees
- BCG N/A
- RPTX N/A
- Industry
- BCG
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- RPTX Health Care
- Exchange
- BCG Nasdaq
- RPTX Nasdaq
- Market Cap
- BCG 48.1M
- RPTX 54.4M
- IPO Year
- BCG N/A
- RPTX 2020
- Fundamental
- Price
- BCG $2.55
- RPTX $1.28
- Analyst Decision
- BCG
- RPTX Strong Buy
- Analyst Count
- BCG 0
- RPTX 3
- Target Price
- BCG N/A
- RPTX $7.00
- AVG Volume (30 Days)
- BCG 542.2K
- RPTX 583.7K
- Earning Date
- BCG 02-26-2025
- RPTX 02-26-2025
- Dividend Yield
- BCG N/A
- RPTX N/A
- EPS Growth
- BCG N/A
- RPTX N/A
- EPS
- BCG N/A
- RPTX N/A
- Revenue
- BCG $161,721,000.00
- RPTX $66,524,000.00
- Revenue This Year
- BCG N/A
- RPTX $11.80
- Revenue Next Year
- BCG N/A
- RPTX N/A
- P/E Ratio
- BCG N/A
- RPTX N/A
- Revenue Growth
- BCG N/A
- RPTX 18.19
- 52 Week Low
- BCG $1.85
- RPTX $1.20
- 52 Week High
- BCG $16.61
- RPTX $8.49
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- RPTX 33.94
- Support Level
- BCG N/A
- RPTX $1.24
- Resistance Level
- BCG N/A
- RPTX $1.36
- Average True Range (ATR)
- BCG 0.00
- RPTX 0.10
- MACD
- BCG 0.00
- RPTX 0.06
- Stochastic Oscillator
- BCG 0.00
- RPTX 28.57
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.